Cancer Biomarkers Market by Type and Application - Global Industry Analysis & Forecast to 2027
Published On : January 2020 Pages : 160 Category: Chemicals & Nanomaterials Report Code : CM018057
Cancer Biomarkers Market by Type (Genetic Biomarkers, Protein Biomarkers) Application (Breast Cancer, Colorectal Cancer, Blood Cancer, Ovarian Cancer, Liver Cancer, Stomach Cancer, Prostate Cancer, Melanoma, Lung Cancer) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Cancer Biomarkers Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. The worldwide cancer biomarker showcase is for the most part isolated under scarcely any classes, for example, test type, sickness sign, and provincial investigations. As for test type, CTC tests, CA tests, BRCA tests, CEA tests, KRAS mutation tests, EGFR mutation test, ALK tests, HER2 tests, AFP tests, PSA tests, and others are fragments. Under illness sign, lung cancer, melanoma, prostate cancer, stomach cancer, ovarian cancer, liver cancer, blood cancer, colorectal cancer, breast cancer, and others, contain significant portions in eh worldwide malignant growth biomarkers showcase. The cancer biomarkers provide a healthy impetus in the associated market.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Abbott Laboratories
- Qiagen NV
- Thermo Fisher Scientific Inc.
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- Hologic,Inc.
- Illumina,Inc.
- Novartis AG
- Agilent Technologies
- BioMerieux SA
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Cancer Biomarkers Market , By Type, Estimates and Forecast, 2017-2027 ($Million)
o Genetic Biomarkers
o Protein Biomarkers
· Cancer Biomarkers Market , By Application, Estimates and Forecast, 2017-2027 ($Million)
o Breast Cancer
o Colorectal Cancer
o Blood Cancer
o Ovarian Cancer
o Liver Cancer
o Stomach Cancer
o Prostate Cancer
o Melanoma
o Lung Cancer
· Cancer Biomarkers Market , By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Abbott Laboratories
o Qiagen NV
o Thermo Fisher Scientific Inc.
o Merck & Co., Inc.
o F. Hoffmann-La Roche Ltd
o Hologic,Inc.
o Illumina,Inc.
o Novartis AG
o Agilent Technologies
o BioMerieux SA
· Cancer Biomarkers Market , By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Cancer Biomarkers Market , By Country
o U.S. Cancer Biomarkers Market
o Canada Cancer Biomarkers Market
o Mexico Cancer Biomarkers Market
o Europe
§ Europe Cancer Biomarkers Market , By Country
o Germany Cancer Biomarkers Market
o UK Cancer Biomarkers Market
o France Cancer Biomarkers Market
o Russia Cancer Biomarkers Market
o Italy Cancer Biomarkers Market
o Rest of Europe Cancer Biomarkers Market
o Asia-Pacific
§ Asia-Pacific Cancer Biomarkers Market , By Country
o China Cancer Biomarkers Market
o Japan Cancer Biomarkers Market
o South Korea Cancer Biomarkers Market
o India Cancer Biomarkers Market
o Southeast Asia Cancer Biomarkers Market
o Rest of Asia-Pacific Cancer Biomarkers Market
o South America
§ South America Cancer Biomarkers Market
o Brazil Cancer Biomarkers Market
o Argentina Cancer Biomarkers Market
o Columbia Cancer Biomarkers Market
o Rest of South America Cancer Biomarkers Market
o Middle East and Africa
§ Middle East and Africa Cancer Biomarkers Market
o Saudi Arabia Cancer Biomarkers Market
o UAE Cancer Biomarkers Market
o Egypt Cancer Biomarkers Market
o Nigeria Cancer Biomarkers Market
o South Africa Cancer Biomarkers Market
o Rest of MEA Cancer Biomarkers Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Cancer Biomarkers Market, By Type
5.1. Introduction
5.2. Global Cancer Biomarkers Revenue and Market Share by Type (2017-2027)
5.2.1. Global Cancer Biomarkers Revenue and Revenue Share by Type (2017-2027)
5.3. Genetic Biomarkers
5.3.1. Global Genetic Biomarkers Revenue and Growth Rate (2017-2027)
5.4. Protein Biomarkers
5.4.1. Global Protein Biomarkers Revenue and Growth Rate (2017-2027)
6. Cancer Biomarkers Market, By Application
6.1. Introduction
6.2. Global Cancer Biomarkers Revenue and Market Share by Application (2017-2027)
6.2.1. Global Cancer Biomarkers Revenue and Revenue Share by Application (2017-2027)
6.3. Breast Cancer
6.3.1. Global Breast Cancer Revenue and Growth Rate (2017-2027)
6.4. Colorectal Cancer
6.4.1. Global Colorectal Cancer Revenue and Growth Rate (2017-2027)
6.5. Blood Cancer
6.5.1. Global Blood Cancer Revenue and Growth Rate (2017-2027)
6.6. Ovarian Cancer
6.6.1. Global Ovarian Cancer Revenue and Growth Rate (2017-2027)
6.7. Liver Cancer
6.7.1. Global Liver Cancer Revenue and Growth Rate (2017-2027)
6.8. Stomach Cancer
6.8.1. Global Stomach Cancer Revenue and Growth Rate (2017-2027)
6.9. Prostate Cancer
6.9.1. Global Prostate Cancer Revenue and Growth Rate (2017-2027)
6.10. Melanoma
6.10.1. Global Melanoma Revenue and Growth Rate (2017-2027)
6.11. Lung Cancer
6.11.1. Global Lung Cancer Revenue and Growth Rate (2017-2027)
7. Cancer Biomarkers Market, By Region
7.1. Introduction
7.2. Global Cancer Biomarkers Revenue and Market Share by Regions
7.2.1. Global Cancer Biomarkers Revenue by Regions (2017-2027)
7.3. North America Cancer Biomarkers by Countries
7.3.1. North America Cancer Biomarkers Revenue and Growth Rate (2017-2027)
7.3.2. North America Cancer Biomarkers Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Cancer Biomarkers by Countries
7.4.1. Europe Cancer Biomarkers Revenue and Growth Rate (2017-2027)
7.4.2. Europe Cancer Biomarkers Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Cancer Biomarkers by Countries
7.5.1. Asia-Pacific Cancer Biomarkers Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Cancer Biomarkers Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Cancer Biomarkers by Countries
7.6.1. South America Cancer Biomarkers Revenue and Growth Rate (2017-2027)
7.6.2. South America Cancer Biomarkers Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Cancer Biomarkers by Countries
7.7.1. Middle East and Africa Cancer Biomarkers Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Cancer Biomarkers Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. • Abbott Laboratories
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. • Qiagen NV
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. • Thermo Fisher Scientific Inc.
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. • Merck & Co., Inc.
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. • F. Hoffmann-La Roche Ltd
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. • Hologic,Inc.
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. • Illumina,Inc.
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. • Novartis AG
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. • Agilent Technologies
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
8.10. • BioMerieux SA
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Financial Overview
9. Cancer Biomarkers Market Forecast (2017-2027)
9.1. Global Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Cancer Biomarkers Market Forecast by Regions (2017-2027)
9.2.1. North America Cancer Biomarkers Market Forecast (2017-2027)
9.2.1.1. United States Cancer Biomarkers Market Forecast (2017-2027)
9.2.1.2. Canada Cancer Biomarkers Market Forecast (2017-2027)
9.2.1.3. Mexico Cancer Biomarkers Market Forecast (2017-2027)
9.2.2. Europe Cancer Biomarkers Market Forecast (2017-2027)
9.2.2.1. Germany Cancer Biomarkers Market Forecast (2017-2027)
9.2.2.2. France Cancer Biomarkers Market Forecast (2017-2027)
9.2.2.3. UK Cancer Biomarkers Market Forecast (2017-2027)
9.2.2.4. Russia Cancer Biomarkers Market Forecast (2017-2027)
9.2.2.5. Italy Cancer Biomarkers Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Cancer Biomarkers Market Forecast (2017-2027)
9.2.3. Asia-Pacific Cancer Biomarkers Market Forecast (2017-2027)
9.2.3.1. China Cancer Biomarkers Market Forecast (2017-2027)
9.2.3.2. Japan Cancer Biomarkers Market Forecast (2017-2027)
9.2.3.3. Korea Cancer Biomarkers Market Forecast (2017-2027)
9.2.3.4. India Cancer Biomarkers Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Cancer Biomarkers Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Cancer Biomarkers Market Forecast (2017-2027)
9.2.4. South America Cancer Biomarkers Market Forecast (2017-2027)
9.2.4.1. Brazil Cancer Biomarkers Market Forecast (2017-2027)
9.2.4.2. Argentina Cancer Biomarkers Market Forecast (2017-2027)
9.2.4.3. Columbia Cancer Biomarkers Market Forecast (2017-2027)
9.2.4.4. Rest of South America Cancer Biomarkers Market Forecast (2017-2027)
9.2.5. Middle East and Africa Cancer Biomarkers Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Cancer Biomarkers Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Cancer Biomarkers Market Forecast (2017-2027)
9.2.5.3. Egypt Cancer Biomarkers Market Forecast (2017-2027)
9.2.5.4. Nigeria Cancer Biomarkers Market Forecast (2017-2027)
9.2.5.5. South Africa Cancer Biomarkers Market Forecast (2017-2027)
9.2.5.6. Turkey Cancer Biomarkers Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Cancer Biomarkers Market Forecast (2017-2027)
9.3. Cancer Biomarkers Market Forecast by Type (2017-2027)
9.3.1. Cancer Biomarkers Forecast by Type (2017-2027)
9.3.2. Cancer Biomarkers Market Share Forecast by Type (2017-2027)
9.4. Cancer Biomarkers Market Forecast by Application (2017-2027)
9.4.1. Cancer Biomarkers Forecast by Application (2017-2027)
9.4.2. Cancer Biomarkers Market Share Forecast by Application (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Cancer Biomarkers Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Cancer Biomarkers Revenue and Revenue Share by Type (2017-2018)
Figure Global Genetic Biomarkers Revenue and Growth Rate (2017-2018)
Figure Global Protein Biomarkers Revenue and Growth Rate (2017-2018)
Table Global Cancer Biomarkers Revenue and Revenue Share by Application (2017-2018)
Figure Global Breast Cancer Revenue and Growth Rate (2017-2018)
Figure Global Colorectal Cancer Revenue and Growth Rate (2017-2018)
Figure Global Blood Cancer Revenue and Growth Rate (2017-2018)
Figure Global Ovarian Cancer Revenue and Growth Rate (2017-2018)
Figure Global Liver Cancer Revenue and Growth Rate (2017-2018)
Figure Global Stomach Cancer Revenue and Growth Rate (2017-2018)
Figure Global Prostate Cancer Revenue and Growth Rate (2017-2018)
Figure Global Melanoma Revenue and Growth Rate (2017-2018)
Figure Global Lung Cancer Revenue and Growth Rate (2017-2018)
Table Global Cancer Biomarkers Revenue by Regions (2017-2018)
Figure North America Cancer Biomarkers Growth Rate (2017-2018)
Figure North America Cancer Biomarkers Revenue and Growth Rate (2017-2018)
Figure North America Cancer Biomarkers by Countries (2017-2018)
Figure North America Cancer Biomarkers Revenue (Million USD) by Countries (2017-2018)
Figure United States Cancer Biomarkers Growth Rate (2017-2018)
Figure United States Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Cancer Biomarkers Growth Rate (2017-2018)
Figure Canada Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Cancer Biomarkers Growth Rate (2017-2018)
Figure Mexico Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Cancer Biomarkers Growth Rate (2017-2018)
Figure Europe Cancer Biomarkers Revenue and Growth Rate (2017-2018)
Figure Europe Cancer Biomarkers by Countries (2017-2018)
Figure Europe Cancer Biomarkers Revenue (Million USD) by Countries (2017-2018)
Figure Germany Cancer Biomarkers Growth Rate (2017-2018)
Figure Germany Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Cancer Biomarkers Growth Rate (2017-2018)
Figure France Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Cancer Biomarkers Growth Rate (2017-2018)
Figure UK Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Cancer Biomarkers Growth Rate (2017-2018)
Figure Russia Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Cancer Biomarkers Growth Rate (2017-2018)
Figure Italy Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Cancer Biomarkers Growth Rate (2017-2018)
Figure Rest of Europe Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Cancer Biomarkers Growth Rate (2017-2018)
Figure Asia-Pacific Cancer Biomarkers Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Cancer Biomarkers by Countries (2017-2018)
Figure Asia-Pacific Cancer Biomarkers Revenue (Million USD) by Countries (2017-2018)
Figure China Cancer Biomarkers Growth Rate (2017-2018)
Figure China Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Cancer Biomarkers Growth Rate (2017-2018)
Figure Japan Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Cancer Biomarkers Growth Rate (2017-2018)
Figure Korea Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Cancer Biomarkers Growth Rate (2017-2018)
Figure India Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Cancer Biomarkers Growth Rate (2017-2018)
Figure Southeast Asia Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Cancer Biomarkers Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Cancer Biomarkers Growth Rate (2017-2018)
Figure South America Cancer Biomarkers Revenue and Growth Rate (2017-2018)
Figure South America Cancer Biomarkers by Countries (2017-2018)
Figure South America Cancer Biomarkers Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Cancer Biomarkers Growth Rate (2017-2018)
Figure Brazil Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Cancer Biomarkers Growth Rate (2017-2018)
Figure Argentina Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Cancer Biomarkers Growth Rate (2017-2018)
Figure Columbia Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Cancer Biomarkers Growth Rate (2017-2018)
Figure Rest of South America Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Cancer Biomarkers Growth Rate (2017-2018)
Figure Middle East and Africa Cancer Biomarkers Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Cancer Biomarkers by Countries (2017-2018)
Figure Middle East and Africa Cancer Biomarkers Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Cancer Biomarkers Growth Rate (2017-2018)
Figure Saudi Arabia Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Cancer Biomarkers Growth Rate (2017-2018)
Figure United Arab Emirates Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Cancer Biomarkers Growth Rate (2017-2018)
Figure Egypt Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Cancer Biomarkers Growth Rate (2017-2018)
Figure Nigeria Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Cancer Biomarkers Growth Rate (2017-2018)
Figure South Africa Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Cancer Biomarkers Growth Rate (2017-2018)
Figure Turkey Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Cancer Biomarkers Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2017-2018)
Table • Abbott Laboratories Cancer Biomarkers Financial Overview
Table • Qiagen NV Cancer Biomarkers Financial Overview
Table • Thermo Fisher Scientific Inc. Cancer Biomarkers Financial Overview
Table • Merck & Co., Inc. Cancer Biomarkers Financial Overview
Table • F. Hoffmann-La Roche Ltd Cancer Biomarkers Financial Overview
Table • Hologic,Inc. Cancer Biomarkers Financial Overview
Table • Illumina,Inc. Cancer Biomarkers Financial Overview
Table • Novartis AG Cancer Biomarkers Financial Overview
Table • Agilent Technologies Cancer Biomarkers Financial Overview
Table • BioMerieux SA Cancer Biomarkers Financial Overview
Figure Global Cancer Biomarkers Revenue (Millions USD) and Growth Rate (2018-2025)
Table Cancer Biomarkers Market Forecast by Regions (2018-2025)
Figure North America Cancer Biomarkers Market Forecast (2018-2025)
Figure United States Cancer Biomarkers Market Forecast (2018-2025)
Figure Canada Cancer Biomarkers Market Forecast (2018-2025)
Figure Mexico Cancer Biomarkers Market Forecast (2018-2025)
Figure Europe Cancer Biomarkers Market Forecast (2018-2025)
Figure Germany Cancer Biomarkers Market Forecast (2018-2025)
Figure France Cancer Biomarkers Market Forecast (2018-2025)
Figure UK Cancer Biomarkers Market Forecast (2018-2025)
Figure Russia Cancer Biomarkers Market Forecast (2018-2025)
Figure Italy Cancer Biomarkers Market Forecast (2018-2025)
Figure Rest of Europe Cancer Biomarkers Market Forecast (2018-2025)
Figure Asia-Pacific Cancer Biomarkers Market Forecast (2018-2025)
Figure China Cancer Biomarkers Market Forecast (2018-2025)
Figure Japan Cancer Biomarkers Market Forecast (2018-2025)
Figure Korea Cancer Biomarkers Market Forecast (2018-2025)
Figure India Cancer Biomarkers Market Forecast (2018-2025)
Figure Southeast Asia Cancer Biomarkers Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Cancer Biomarkers Market Forecast (2018-2025)
Figure South America Cancer Biomarkers Market Forecast (2018-2025)
Figure Brazil Cancer Biomarkers Market Forecast (2018-2025)
Figure Argentina Cancer Biomarkers Market Forecast (2018-2025)
Figure Columbia Cancer Biomarkers Market Forecast (2018-2025)
Figure Rest of South America Cancer Biomarkers Market Forecast (2018-2025)
Figure Middle East and Africa Cancer Biomarkers Market Forecast (2018-2025)
Figure Saudi Arabia Cancer Biomarkers Market Forecast (2018-2025)
Figure United Arab Emirates Cancer Biomarkers Market Forecast (2018-2025)
Figure Egypt Cancer Biomarkers Market Forecast (2018-2025)
Figure Nigeria Cancer Biomarkers Market Forecast (2018-2025)
Figure South Africa Cancer Biomarkers Market Forecast (2018-2025)
Figure Turkey Cancer Biomarkers Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Cancer Biomarkers Market Forecast (2018-2025)
Figure Global Cancer Biomarkers Forecast by Type (2018-2025)
Figure Global Cancer Biomarkers Market Share Forecast by Type (2018-2025)
Figure Global Cancer Biomarkers Forecast by Type (2018-2025)
Figure Global Cancer Biomarkers Forecast by Application (2018-2025)
Figure Global Cancer Biomarkers Market Share Forecast by Application (2018-2025)
Figure Global Cancer Biomarkers Forecast by Application (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|